Patrick Aisher joins ReBio Pharma as Non-Executive Member of the Board of Directors

Turku, Finland – ReBio Pharma announced today that Patrick Aisher has joined the team as a Non-Executive Member of its Board of Directors.

Aisher is Chairman of Kinled Holding in Hong King, which retains a portfolio of more than 100 investments in the life science, digital, and financial technology industries. He is co-founder of CEBINA, the Central European Biotechnology Incubator and Accelerator in Vienna Austria. Aisher also is a co-founder of Mountain Labs AG in Zürich, Switzerland.

“Patrick brings impressive experience in entrepreneurship and fundraising to ReBio Pharma and will be instrumental in helping us fulfill our mission to transform the standard of care for people living with chronic eye disease,” says Vinod Vijayakumar, DPhil, CEO of ReBio Pharma. “We’re thrilled to have his guidance as part of our Board of Directors.”

About ReBio Pharma

ReBio Pharma is a pre-clinical stage biotechnology company that has developed SiSu®, a novel, proprietary formulation technology that solves the safety and efficacy challenges other sustained release approaches have been unable to resolve. SiSu® is designed to steadily release effective levels of therapeutics within the eye while safely dissolving once drug release is completed, and can be tuned to the drug, indication, and duration of release required. ReBio Pharma is leveraging Sisu® to create a new franchise to transform the standard of care in the treatment of vision-threatening chronic eye diseases. Discover more at www.rebiopharma.com.